---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-25-000099"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:42:33.439791+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Elicio Therapeutics announces IDMC positive recommendation to continue Phase 2 pancreatic cancer trial to final analysis

## Summary
- IDMC recommended AMPLIFY-7P trial continue to final analysis without modifications based on pre-specified interim review of safety and efficacy.
- Final disease-free survival analysis anticipated in Q4 2025; company remains blinded to trial outcomes.
- Cash runway extends into Q1 2026, past the expected final DFS readout.
- Elicio previously reached FDA alignment on key elements of planned pivotal Phase 3 study design.
- ELI-002 7P is an off-the-shelf immunotherapy targeting seven KRAS mutations in pancreatic ductal adenocarcinoma.

## SEC filing metadata
- accession: 0001601485-25-000099
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000099/0001601485-25-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000099/angn-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-25-000099
- JSON: https://secwatch.observer/filing/0001601485-25-000099.json
- Plain text: https://secwatch.observer/filing/0001601485-25-000099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.